# Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children

> **NCT03111069** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Malignant Neoplasms of Mesothelial and Soft Tissue
- Rhabdomyosarcoma, Pelvic
- Rhabdomyosarcoma, Abdominal

## Interventions

- **PROCEDURE:** Abdominal Surgery
- **DRUG:** Doxorubicin
- **RADIATION:** Intra-Operative Radiation

## Key facts

- **NCT ID:** NCT03111069
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-08
- **Primary completion:** 2021-08
- **Final completion:** 2021-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI withdrew study
- **Last updated:** 2018-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03111069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03111069, "Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03111069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*